A recent feature in Value and Outcomes Spotlight, a publication by the International Society for Pharmacoeconomics and Outcomes Research, delves into how the health industry is undertaking value assessments for cancer immunotherapies.
Christiane Truelove in her write up discusses how European countries conduct value assessments, and how they stack up against the U.S.’s approach.
“Most of the United States has a different approach; particularly in the public sector, there are not really any assessments for economics or value,” University of York’s Michael Drummond said. “CMS approves everything in cancer as soon as the FDA licenses the drug.”
